RAD51-DEPENDENT HOMOLOGOUS RECOMBINATION RESTORATION AND PARP INHIBITOR RESISTANCE IN BRCA-MUTATED OVARIAN CANCER: MOLECULAR MECHANISMS, BIOMARKERS, AND THERAPEUTIC STRATEGIES — AN UMBRELLA REVIEW

Background: Poly (ADP-ribose) polymerase inhibitors exploit synthetic lethality in homologous recombination-deficient ovarian cancer, particularly in carcinomas harboring pathogenic BRCA alterations. However, resistance frequently emerges when DNA repair capacity or replication-fork stability is restored. The functional recovery of homologous recombination mediated by the recombinase RAD51 represents a central mechanism underlying therapeutic failure. Methods: In this umbrella review, four clinical systematic reviews and meta-analyses were synthesized to evaluate progression-free and overall survival outcomes across molecular strata without de novo pooling due to primary trial overlap. Fifteen translational cohorts were integrated to evaluate secondary BRCA reversion mutations, functional RAD51 foci formation assays, circulating tumor DNA monitoring, and resistance-directed combination strategies. Results: Systematic review evidence confirms substantial progression-free survival benefit from maintenance inhibitor therapy in BRCA-mutated cohorts, with intermediate benefits in homologous recombination-deficient cohorts and attenuated gains in repair-proficient disease. Therapeutic resistance arises through secondary reading-frame reversions in BRCA and RAD51 genes, alteration of 53BP1-shieldin end-resection complexes, stabilization of replication forks by SNF2-family remodelers, and epigenetic reactivation. Functional RAD51 foci assays identify dynamic repair competence across archival specimens, while longitudinal circulating tumor DNA detects emerging resistant clones prior to radiological progression. Early-phase combinations targeting checkpoint kinases demonstrate objective responses in resistant tumors. Conclusion: RAD51-dependent homologous recombination recovery provides a cohesive functional framework for acquired inhibitor failure. Dynamic functional assays and longitudinal liquid biopsies offer essential predictive utility to overcome the limitations of static genomic markers in guiding tailored intervention.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24332386
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

RAD51-DEPENDENT HOMOLOGOUS RECOMBINATION RESTORATION AND PARP INHIBITOR RESISTANCE IN BRCA-MUTATED OVARIAN CANCER: MOLECULAR MECHANISMS, BIOMARKERS, AND THERAPEUTIC STRATEGIES — AN UMBRELLA REVIEW

Abhisek Chaudhary, Riyad Hossain, Saheli Patra, Shibankar Debnath et al.
4 links
Zenodo (CERN European Organization for Nuclear Research)
PARP inhibition in cancer therapy
article

RAD51-DEPENDENT HOMOLOGOUS RECOMBINATION RESTORATION AND PARP INHIBITOR RESISTANCE IN BRCA-MUTATED OVARIAN CANCER: MOLECULAR MECHANISMS, BIOMARKERS, AND THERAPEUTIC STRATEGIES — AN UMBRELLA REVIEW

Abhisek Chaudhary, Riyad Hossain, Saheli Patra, Shibankar Debnath, Dhruva Narayan K., Onkar Kumar Yadav, Ronic Saha, Ritikesh Das, Tapomay Bhanja
article en

Abstract

Background: Poly (ADP-ribose) polymerase inhibitors exploit synthetic lethality in homologous recombination-deficient ovarian cancer, particularly in carcinomas harboring pathogenic BRCA alterations. However, resistance frequently emerges when DNA repair capacity or replication-fork stability is restored. The functional recovery of homologous recombination mediated by the recombinase RAD51 represents a central mechanism underlying therapeutic failure. Methods: In this umbrella review, four clinical systematic reviews and meta-analyses were synthesized to evaluate progression-free and overall survival outcomes across molecular strata without de novo pooling due to primary trial overlap. Fifteen translational cohorts were integrated to evaluate secondary BRCA reversion mutations, functional RAD51 foci formation assays, circulating tumor DNA monitoring, and resistance-directed combination strategies. Results: Systematic review evidence confirms substantial progression-free survival benefit from maintenance inhibitor therapy in BRCA-mutated cohorts, with intermediate benefits in homologous recombination-deficient cohorts and attenuated gains in repair-proficient disease. Therapeutic resistance arises through secondary reading-frame reversions in BRCA and RAD51 genes, alteration of 53BP1-shieldin end-resection complexes, stabilization of replication forks by SNF2-family remodelers, and epigenetic reactivation. Functional RAD51 foci assays identify dynamic repair competence across archival specimens, while longitudinal circulating tumor DNA detects emerging resistant clones prior to radiological progression. Early-phase combinations targeting checkpoint kinases demonstrate objective responses in resistant tumors. Conclusion: RAD51-dependent homologous recombination recovery provides a cohesive functional framework for acquired inhibitor failure. Dynamic functional assays and longitudinal liquid biopsies offer essential predictive utility to overcome the limitations of static genomic markers in guiding tailored intervention.

Zenodo (CERN European Organization for Nuclear Research)
Al-Ameen College of Pharmacy (IN)
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon